Prototype/XBB.1.5 Bivalent Vaccine (5 µg)

Drug identity checked against registry records

Also recorded as Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesNCT05973006NovavaxPhase 3Completed2024-04-01Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.